Price (delayed)
$58.25
Market cap
$5.49B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.64
Enterprise value
$5.39B
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this
There are no recent dividends present for ITCI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.